Nano Dimension Ltd · NASDAQ:NNDM
Nano Dimension — SPAC Merger (June 2026)
30 slides from Nano Dimension's SPAC merger presentation, Jun 15, 2026
Slide 1: Proposed Business Combination: Nano Dimension + Infinite Epigenetics
PROPOSED BUSINESS COMBINATION Nano Dimension + Infinite Epigenetics Forming a publicly traded AI - powered company to redefine how chronic disease is predicted, detected and prevented with epigenetics. 01
Slide 2: Forward-looking statements & disclaimer
DISCLAIMER Forward - looking statements & disclaimer. Forward Looking Statements Additional Information and Where to Find It Participants in the Solicitation 02
Slide 3: Contents
Contents 19 Healthcare Provider Market Opportunity 20 Additional Market Opportunities 21 Commercial Applications 22 Market Precedents 23 The Infinite Portfolio 24 Leadership 25 Our Partners 27 Our Investors 28 Key Takeaways 30 Reference Glossary 04 Transaction Overview 07 What This Creates 09 The Pr
Slide 4: Nano Dimension brings capital and Nasdaq listing; Infinite brings AI platform
NANO DIMENSION BRINGS Strong capital base and Nasdaq listing A Nasdaq listing, a strong capital base, and the strategic flexibility to fund growth. + INFINITE EPIGENETICS BRINGS A revenue - generating, biological AI platform A vast, proprietary biological dataset, deep IP, and biological AI foundati
Slide 5: Summary of potential opportunities review
TRANSACTION OVERVIEW Summary of potential opportunities review. review. 05 Nano Dimension engaged Guggenheim Securities, LLC (“Guggenheim”) and Houlihan Lokey (“Houlihan”) to support the Nano Dimension’s Board of Directors in conducting a thorough and disciplined evaluation of a comprehensive range
Slide 6: Summary of key terms
TRANSACTION OVERVIEW Summary of key terms. terms. 06 Signed Term Sheet: June 15, 2026 Definitive Agreement expected to be executed before July 31, 2026 The combined company is expected to operate under the Infinite Epigenetics name and continue trading on the Nasdaq Capital Market under the proposed
Slide 7: What this creates
WHAT THIS CREATES An AI - powered preventive health and diagnostics company on company on Nasdaq. The proposed combination would bring Infinite Epigenetics, its proprietary biological AI platform and revenue - generating diagnos tics operations, to the public market under the ticker IEAI. Commercial
Slide 8: Every few seconds someone dies from chronic disease
EVERY 11 SECONDS Someone in the world dies from COPD. EVERY 9 SECONDS Someone in the world dies of diabetes. EVERY 2 SECONDS Someone in the world dies of cardiovascular disease. Sources: WHO, “Chronic Obstructive Pulmonary Disease (COPD),” 2026; WHO, “Cardiovascular Diseases,” 2026; International Di
Slide 9: The Problem: Chronic diseases cause ~75% of deaths worldwide
THE PROBLEM Chronic diseases cause ~75% of deaths worldwide. worldwide. Today's diagnostics are failing us. They are reactive, confirming disease after symptoms appear, often years after the biolog y h as already changed. The cost of that delay is measured in trillions, and in countless lives. >4 Bi
Slide 10: What if you could predict or diagnose these diseases years before symptoms arise?
What if you could predict or diagnose these diseases with remarkable precision , years before symptoms arise? 10
Slide 11: Infinite Epigenetics Overview
INFINITE EPIGENETICS OVERVIEW We built the platform that makes it possible. Infinite's proprietary biological AI model is trained on the most information - dense biological signal that exists: the epigenome . Until AI, no one could interpret it at scale. Now, we can predict disease years earlier and
Slide 12: Why Now
WHY NOW For the first time, AI can interpret epigenetics at scale. Two forces are arriving at once. Epigenetics has become a validated, dynamic readout of the body, and AI has become powerful and cheap enough to interpret it at scale. Infinite sits at the intersection. EPIGENETICS IS NO LONGER EXPER
Slide 13: We read the operating system of the body
MORE ADOPTION MORE DATA SMARTER MODELS DEEPER INSIGHTS 13 ONE - LINER We read the operating system of the body – and use AI to translate it into earlier diagnosis and better care.
Slide 14: How the Test Works
HOW THE TEST WORKS A simple at - home blood collection powers millions of health insights. 01 At - Home Blood Collection A small blood sample, collected at home or in clinic. 02 Lab Processing Our CLIA - certified lab reads 1M+ epigenetic signals from a single sample. 03 AI Translation Our foundatio
Slide 15: Our Proprietary Model
OUR PROPRIETARY MODEL How the proprietary AI model works. Infinite Epigenetics pairs one of the world's largest epigenetic datasets with a biological AI foundation model trained on bi lli ons data points - redefining how disease is predicted, detected, and prevented. Methylation array: the lab test
Slide 16: Our Data Flywheel
OUR DATA FLYWHEEL Why it’s hard to replicate . Most diagnostics companies have an AI chatbot. We have a flywheel – with five years of patent filings, proprietary know - how, and a compounding data asset – widening the gap between us and any future competitor. 120K + samples collected. Every one made
Slide 17: The Market Size
THE MARKET SIZE Starting with four large, underdiagnosed populations . Our initial focus is on four large chronic disease markets where novel diagnostic technologies can drive the biggest impact, wit h a clear roadmap for future entry into additional disease markets beyond these four. Cardiovascular
Slide 18: Performance vs. Existing Diagnostics
PERFORMANCE VS. EXISTING DIAGNOSTICS Strong performance versus standard tools across four major chronic diseases. Across major chronic diseases, our models show AUCs (area under the ROC curve) of 0.85 – 0.96. AUC measures how well a model separ ates people with a condition from those without it: 0.5
Slide 19: Healthcare Provider Market Opportunity
HEALTHCARE PROVIDER MARKET OPPORTUNITY $94B prevalence TAM today. today. INDICATION PREVALENCE TAM WHAT WE DETECT Type 2 Diabetes $42.9B 5 - year T2D risk in prediabetes and metabolic - risk adults. Cardiovascular Disease $22.3B 5 - year ASCVD risk for intermediate - risk primary - prevention adults
Slide 20: Additional Market Opportunities
ADDITIONAL MARKET OPPORTUNITIES Near - zero incremental cost for new markets. The same finger prick that catches diabetes early can also enrich a pharma trial and screen a military unit. Healthcare Providers Providers CURRENT MARKET DTC & Commercial Partnerships Partnerships CURRENT MARKET Research
Slide 21: Commercial Applications
COMMERCIAL APPLICATIONS The possibilities of what we can learn are infinite . Our proprietary biological AI model is designed to support earlier disease - risk detection, treatment - response modeling, biologic al - age measurement, and other applications on one shared model. Each test expands the d
Slide 22: Market Precedents
MARKET PRECEDENTS Three companies with multi billion - dollar validations. Infinite does all of it, from one platform. Exact Sciences proved diagnostics can scale in the public market. GRAIL proved methylation works. Tempus proved data plus AI is a platform. Infinite Epigenetics is where all three c
Slide 23: The Infinite Portfolio
THE INFINITE PORTFOLIO One data engine, multiple brands . Infinite Epigenetics powers clinical diagnostics and longevity solutions across its portfolio with one biological data engine . E very test that TruDiagnostic and Tally run expands the shared biological data asset, so the entire platform gets
Slide 24: Leadership
LEADERSHIP A team that has done this before . Proven operators paired with the scientists who authored the field, with $20B+ in combined exits behind the founding team. CO - FOUNDER Matt Dawson, MD Chief Executive Officer Six - time healthcare founder with multiple exits Author of two medical textbo
Slide 25: Our Partners
OUR PARTNERS Built with leading institutions . Relationships span research collaborations, data - use agreements, and licensed IP across leading institutions. PEER - REVIEWED STUDIES 50 + DUAS & COLLABORATIONS 80 + DUA: data - use agreement governing how a partner's data may be accessed and used Rel
Slide 26: Science, clinical, and governmental advisors
OUR PARTNERS Science, clinical, and governmental advisors. VADM (Ret.) Rocky Bono, MD Former CEO, Defense Health Agency David Shulkin, MD 9th Secretary, U.S. Veterans Affairs Gen. (Ret.) Michael Garrett U.S. Army Gen. (Ret.) Paul Funk U.S. Army Gen. (Ret.) Ed Daly U.S. Army MG (Ret.) Dennis LeMaster
Slide 27: Our Investors
27 Brad Keywell AI in healthcare will not be defined by chatbots alone. We believe the most valuable healthcare AI platforms will be built on proprietary biological data. Infinite Epigenetics has the opportunity to bring that platform logic to epigenetics, one of the most powerful and dynamic data l
Slide 28: Key Takeaways
KEY TAKEAWAYS Why shareholders should support this transaction. transaction. 01 A proprietary biological AI foundation model 02 Proprietary IP & a vast dataset that can't be replicated 03 A live, revenue - generating diagnostics business today 04 Clear use of capital to scale validation, data, and c
Slide 29: The Thesis, One Last Time
NASDAQ: NNDM → IEAI THE THESIS, ONE LAST TIME One proprietary AI platform. Many clinical answers. A compounding biological data asset. 29
Slide 30: Reference Glossary
REFERENCE Glossary. y. ASCVD AUC Biological Age Biomarker CLIA - certified CpG site DNA Methylation DUA Epigenetics Epigenome Foundation Model Healthspan MASLD / MASH Methylation Array Methylation Probe / Probe Set Multi - Omic ROC curve Term Sheet 30